Biologically Active Small Molecules

CWHM12 is an analog of RGD peptide (Item No. 14501), a tripeptide that inhibits integrin-ligand interactions in studies related to cell adhesion, migration, growth, and differentiation.

A potent, orally bioavailable inhibitor of casein kinase 2 (CK2 Ki = 0.38 nM) inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice.

A potent, orally bioavailable inhibitor of casein kinase 2 (CK2 Ki = 0.38 nM) inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice.

A potent, orally bioavailable inhibitor of casein kinase 2 (CK2 Ki = 0.38 nM) inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice.

A potent, orally bioavailable inhibitor of casein kinase 2 (CK2 Ki = 0.38 nM) inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice.

A selective inhibitor of RNA polymerase I-driven transcription of rRNA (IC₅₀s = 142, 113, and 54 nM in HCT116, A375, and MIA PaCa-2 tumor cells, respectively) demonstrates in vivo antitumor activity against human solid tumors in mouse

A selective inhibitor of RNA polymerase I-driven transcription of rRNA (IC₅₀s = 142, 113, and 54 nM in HCT116, A375, and MIA PaCa-2 tumor cells, respectively) demonstrates in vivo antitumor activity against human solid tumors in mouse

A selective inhibitor of RNA polymerase I-driven transcription of rRNA (IC₅₀s = 142, 113, and 54 nM in HCT116, A375, and MIA PaCa-2 tumor cells, respectively) demonstrates in vivo antitumor activity against human solid tumors in mouse

A selective inhibitor of RNA polymerase I-driven transcription of rRNA (IC₅₀s = 142, 113, and 54 nM in HCT116, A375, and MIA PaCa-2 tumor cells, respectively) demonstrates in vivo antitumor activity against human solid tumors in mouse

A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC₅₀s = 5, 25, and 16 nM, respectively) dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1 acts synergistically with

A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC₅₀s = 5, 25, and 16 nM, respectively) dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1 acts synergistically with

A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC₅₀s = 5, 25, and 16 nM, respectively) dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1 acts synergistically with